Home/Pipeline/AmoyDx PIK3CA Mutation Detection Kit

AmoyDx PIK3CA Mutation Detection Kit

Breast Cancer

CommercialApproved as CDx for risovalisib in Japan

Key Facts

Indication

Breast Cancer

Phase

Commercial

Status

Approved as CDx for risovalisib in Japan

Company

Amoy Diagnostics

About Amoy Diagnostics

A precision oncology diagnostics company developing PCR and NGS-based companion diagnostic kits for cancer, with a focus on accessibility and global partnerships.

View full company profile

Therapeutic Areas

Oncology

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC